<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851108</url>
  </required_header>
  <id_info>
    <org_study_id>UniHD008</org_study_id>
    <nct_id>NCT02851108</nct_id>
  </id_info>
  <brief_title>Methylene Blue Against Falciparum Malaria in Burkina Faso</brief_title>
  <acronym>BlueACTn</acronym>
  <official_title>Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche en Sante de Nouna, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum
      malaria treatment in African children: A randomised controlled trial

      Elimination has become the goal of malaria programmes in an increasing number of endemic
      countries and regions. As resistance against artemisinin compounds has recently started to
      emerge in South-East Asia, there is a clear need to develop alternative malaria drug
      combinations. Adding another anti-malarial with a short half-life such as methylene blue to
      standard ACT (artemisinin-based combination therapy) could be a strategy to prevent
      artemisinin resistance development. Moreover, adding a gametocytocidal drug to ACT reduces
      the probability of transmission of P. falciparum parasites including drug-resistant
      parasites.

      Objectives: The primary objective of this trial is to investigate the safety of artesunate
      (AS) - amodiaquine (AQ) - methylene blue (MB) compared to AS - AQ - primaquine (PQ) in young
      children with uncomplicated falciparum malaria in Burkina Faso.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of the underlying research project is to develop a MB-based first-line drug
      combination regimen against uncomplicated falciparum malaria in SSA.

      The primary objective of this study is: To study the safety of the triple combination
      AS-AQ-MB compared to AS-AQ-PQ in the treatment of uncomplicated falciparum malaria in young
      African children. The secondary objective of this study is: To study the efficacy of this
      MB-based triple combination in comparison with standard ACT-PQ in the treatment of
      uncomplicated falciparum malaria in young African children.

      It is a mono-center, open randomised controlled non-inferiority study in children with
      uncomplicated falciparum malaria in Burkina Faso. Patients will be randomised to two
      treatment groups (arms):

        1. AS-AQ-MB

        2. AS-AQ-PQ

      Study population: Children aged 6-59 months with uncomplicated falciparum malaria from Nouna
      Hospital in north-western Burkina Faso.

      Sample size: 100 patients (50 per study arm).

      Treatment: The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined
      with once daily MB (15 mg/kg) over a three days period. The control group will receive once
      daily a fixed dose AS-AQ over three days combined with a single dose of PQ on day 2 (0.25
      mg/kg).

      Endpoints: Primary endpoint is the haemoglobin value on day 7 compared to baseline. Secondary
      endpoints are adverse events (AE), adequate clinical and parasitological response (ACPR) rate
      (PCR-corrected for recrudescences), as well as gametocyte prevalence and density.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Haemoglobin Compared to the Baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gametocyte Prevalence</measure>
    <time_frame>28 days</time_frame>
    <description>measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>28 days</time_frame>
    <description>Reports of observed or self-reported adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mothers/Caretakers Questionnaire on Acceptance</measure>
    <time_frame>14 days</time_frame>
    <description>Acceptance of the different treatment regimens by mothers/caretakers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gametocyte Density</measure>
    <time_frame>28 days</time_frame>
    <description>measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>AS-AQ-MB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AS-AQ-PQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>50 patients will receive methylene blue</description>
    <arm_group_label>AS-AQ-MB</arm_group_label>
    <other_name>3,7-bis(Dimethylamino)-phenothiazine-5-ium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>50 patients will receive primaquine</description>
    <arm_group_label>AS-AQ-PQ</arm_group_label>
    <other_name>(±)-N4-(6-Methoxychinolin-8-yl)pentan-1,4-diamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥ 6 kg

          -  Uncomplicated malaria caused by P. falciparum

          -  Asexual parasites ≥ 2 000/µl and ≤ 100 000/µl

          -  Axillary temperature ≥ 37.5°C or a history of fever during the last 24 hours

          -  Burkinabe nationality

          -  Permanent residence in the study area with no intention of leaving during the
             surveillance period

          -  Written informed consent of parents or care takers

        Exclusion Criteria:

          -  Severe malaria

          -  Mixed malaria infection

          -  Vomiting (&gt;2 times within 24 hours before the visit)

          -  Any apparent significant disease, including severe malnutrition

          -  A history of a previous, significant adverse reaction or known allergy to one or more
             of the study drugs

          -  Anaemia (haemoglobin &lt; 7 g/dl)

          -  Treated in the same trial before

          -  All modern antimalarial treatment prior to inclusion (last seven days)

          -  Therapy with serotonin reuptake inhibitors (e.g. citalopram, escitalopram, fluoxetine,
             Paroxetine, Sertraline)

          -  Simultaneous participation in another investigational study

          -  Patients with known HIV/AIDS disease

          -  Therapy with drugs known to inhibit the liver enzymes cytochrome 2A6 (e.g.
             methoxsalen, pilocarpine, tranylcypromine) and/or cytochrome 2C8 (e.g. trimethoprim,
             ketoconazole, ritonavir, saquinavir, lopinavir, gemfibrozil, montelukast)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Müller, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRSN</name>
      <address>
        <city>Nouna</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <results_first_submitted>March 11, 2020</results_first_submitted>
  <results_first_submitted_qc>March 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Olaf Mueller</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>falciparum malaria</keyword>
  <keyword>sub saharan</keyword>
  <keyword>africa</keyword>
  <keyword>elimination disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Phenothiazine</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AS-AQ-MB</title>
          <description>Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
Methylene Blue: 50 patients will receive methylene blue</description>
        </group>
        <group group_id="P2">
          <title>AS-AQ-PQ</title>
          <description>Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
Primaquine: 50 patients will receive primaquine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AS-AQ-MB</title>
          <description>Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
Methylene Blue: 50 patients will receive methylene blue</description>
        </group>
        <group group_id="B2">
          <title>AS-AQ-PQ</title>
          <description>Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
Primaquine: 50 patients will receive primaquine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.34" spread="12.34"/>
                    <measurement group_id="B2" value="38.2" spread="13.93"/>
                    <measurement group_id="B3" value="40.27" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.91" spread="3.16"/>
                    <measurement group_id="B2" value="12.18" spread="2.98"/>
                    <measurement group_id="B3" value="12.55" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of current disease episode</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.94" spread="1.32"/>
                    <measurement group_id="B2" value="1.96" spread="1.28"/>
                    <measurement group_id="B3" value="1.95" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment of current disease episode</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any other prior illnesses within last 7 days</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature</title>
          <units>[°C]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.80" spread="0.81"/>
                    <measurement group_id="B2" value="37.79" spread="0.79"/>
                    <measurement group_id="B3" value="37.80" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>[g/dl]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.16" spread="1.62"/>
                    <measurement group_id="B2" value="9.68" spread="1.42"/>
                    <measurement group_id="B3" value="9.92" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>P.falciparum merozoites paras. density</title>
          <units>parasites/µl blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30373.60" spread="32808.10"/>
                    <measurement group_id="B2" value="23318.80" spread="25199.72"/>
                    <measurement group_id="B3" value="26846.20" spread="29319.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>P.falciparum gamotocytes parasite density (for those patients with gametocytes)</title>
          <units>parasites/µl blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200.0" spread="123.29"/>
                    <measurement group_id="B2" value="170.0" spread="110.58"/>
                    <measurement group_id="B3" value="181.54" spread="111.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>G6PD phenotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Deficient</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Heterozygous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Haemoglobin Compared to the Baseline</title>
        <description>Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden)</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AS-AQ-MB</title>
            <description>Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
Methylene Blue: 50 patients will receive methylene blue</description>
          </group>
          <group group_id="O2">
            <title>AS-AQ-PQ</title>
            <description>Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
Primaquine: 50 patients will receive primaquine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haemoglobin Compared to the Baseline</title>
          <description>Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden)</description>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="1.42"/>
                    <measurement group_id="O2" value="0.54" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gametocyte Prevalence</title>
        <description>measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AE)</title>
        <description>Reports of observed or self-reported adverse event</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mothers/Caretakers Questionnaire on Acceptance</title>
        <description>Acceptance of the different treatment regimens by mothers/caretakers</description>
        <time_frame>14 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gametocyte Density</title>
        <description>measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up</description>
        <time_frame>28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AS-AQ-MB</title>
          <description>Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
Methylene Blue: 50 patients will receive methylene blue</description>
        </group>
        <group group_id="E2">
          <title>AS-AQ-PQ</title>
          <description>Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
Primaquine: 50 patients will receive primaquine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Severe malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-intestinal symptoms</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory symptoms</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E2" events="35" subjects_affected="20" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Olaf Müller</name_or_title>
      <organization>Heidelberg University</organization>
      <phone>+49 6221 56 4904</phone>
      <email>olaf.mueller@urz.uni-heidelberg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

